Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia

被引:18
|
作者
Cho, EK
Heo, DS
Seol, JG
Seo, EJ
Chi, HS
Kim, ES
Lee, YY
Kim, BK
Kim, NK
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Haematol Oncol,Canc Res Ctr, Seoul 110744, South Korea
[2] Gachon Med Sch, Gil Med Ctr, Dept Internal Med, Div Haematol Oncol, Inchon, South Korea
[3] Univ Ulsan, Coll Med, Dept Clin Pathol, Seoul, South Korea
[4] Asan Med Ctr, Seoul, South Korea
[5] Han Yang Univ, Coll Med, Dept Internal Med, Div Haematol Oncol, Seoul, South Korea
关键词
chronic myelogenous leukaemia; BCR-ABL rearrangement; fluorescence in situ hybridization; T cells; natural killer cells;
D O I
10.1046/j.1365-2141.2000.02341.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic myelogenous leukaemia (CML) is a haematological malignant disorder characterized by the Philadelphia chromosome (Ph) and BCR-ABL gene rearrangement. This abnormal fusion gene can be considered to serve as a marker for the transformed cell clone in CML and is found in all cells arising from the same malignant precursor cell. It has been detected in CML cells of the myeloid, monocytic, erythroid and B-lymphocytic lineages. However, it is still arguable as to whether T lymphocytes or natural killer (NK) cells carry this marker Answering this question would clarify the ontogenic relationship between NE; cells and T cells. We examined 12 CML patients and studied the expression of BCR-ABL rearrangement by fluorescence in situ hybridization (FISH) in both NK cells and T cells sorted by flow cytometry. The purity of T cells was 95.6-99.8% and that of NK cells was 95.3-99.3% after sorting. Neither NK cells nor T cells showed any positive BCR-ABL signal with the exception of one patient who recovered from a lymphoid blastic crisis. We speculate that T cells and NK cells originate from BCR-ABL-negative stem cells.
引用
收藏
页码:216 / 222
页数:7
相关论文
共 50 条
  • [21] Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells
    Mackay, C. E.
    Allen, E. K.
    Mukhopadhyay, A.
    Karvela, M.
    Holyoake, T. L.
    Jorgensen, H. G.
    Helgason, G. V.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 58 - 58
  • [22] DETECTION OF BCR-ABL PROTEINS IN BLOOD-CELLS OF BENIGN PHASE CHRONIC MYELOGENOUS LEUKEMIA PATIENTS
    GUO, JQ
    WANG, JYJ
    ARLINGHAUS, RB
    CANCER RESEARCH, 1991, 51 (11) : 3048 - 3051
  • [23] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
    Yuan, Hongfeng
    Gao, Chunggang
    Bhatia, Ravi
    Chen, WenYong
    CANCER RESEARCH, 2009, 69
  • [24] Proliferating status of peripheral blood progenitor cells from patients with BCR-ABL positive chronic myelogenous leukemia.
    Krämer, A
    Bergmann, J
    Willer, A
    Reiter, A
    Hochhaus, A
    Hehlmann, R
    BLOOD, 1999, 94 (10) : 533A - 533A
  • [25] Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib
    Wang, L
    Butt, NM
    Atherton, MG
    Clark, RE
    LEUKEMIA, 2004, 18 (05) : 1025 - 1027
  • [26] Can p230(BCR-ABL) myeloproliferative neoplasm be distinguished from chronic myelogenous leukaemia?
    Mayeur-Rousse, Caroline
    Aumerle, Laureen
    Sorel, Nathalie
    Chomel, Jean-Claude
    Turhan, Ali G.
    HEMATOLOGIE, 2009, 15 (06): : 416 - 423
  • [27] BCR-ABL PROTEIN EXPRESSION IN PERIPHERAL-BLOOD CELLS OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS UNDERGOING THERAPY
    GUO, JQ
    LIAN, JY
    XIAN, YM
    LEE, MS
    DEISSEROTH, AB
    STASS, SA
    CHAMPLIN, RE
    TALPAZ, M
    WANG, JYJ
    ARLINGHAUS, RB
    BLOOD, 1994, 83 (12) : 3629 - 3637
  • [28] The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript
    Kang, Ka-Won
    Jung, Jikhan
    Hur, Woojune
    Park, Jaena
    Shin, Hyunku
    Choi, ByeongHyeon
    Jeong, Hyesun
    Kim, Dae Sik
    Yu, Eun Sang
    Lee, Se Ryeon
    Sung, Hwa Jung
    Kim, Seok Jin
    Choi, Chul Won
    Kim, Byung Soo
    Kim, Hyun Koo
    Hong, Sunghoi
    Park, Ji-ho
    Choi, Yeonho
    Park, Yong
    BLOOD, 2017, 130
  • [29] Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)?
    Helgason, G. V.
    Hamilton, A.
    Myssina, S.
    Jorgensen, H. G.
    Bhatia, R.
    Modi, H.
    Schemionek, M.
    Koschmieder, S.
    Brunton, V.
    Holyoake, T. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 72 - 72
  • [30] b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia
    Norbury, LC
    Clark, RE
    Christmas, SE
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) : 616 - 621